Not sure how I missed this news but in the upcoming days this biotech company could very well be the talk of Wall Street !
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech Discusses Major Milestones Ahead of Phase 2b Clinical Trial in Pancreatic Cancer
The trial will test the effectiveness and safety of PharmaCyte Biotech’s pancreatic cancer treatment. This treatment consists of the combination of microcapsules with genetically modified live cells in combination with low doses of the chemotherapy drug ifosfamide. These encapsulated live cells are placed as close to a cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the patient’s cancer.
In the coming weeks and months, a number of major “milestone” tasks will take place that will enable PharmaCyte Biotech’s first clinical trial to commence. Many of these must be completed before a formal Investigational New Drug application (“IND”) is filed with the drug regulatory authorities.
Yes, you read that right : New Drug application (“IND”) with the drug regulatory authorities.
Read the entire press release HERE
PMCB is trading at 0.0914 and it could be just matter of some time before the giants from Wall Street take notice of this undervalued biotech company !
So, take notice now before it's too late !
